Format:
13
ISSN:
1090-2139
Content:
Tumor necrosis factor receptor 2 (TNFR2) is a transmembrane receptor that promotes immune modulation and tissue regeneration and is recognized as a potential therapeutic target for multiple sclerosis (MS). However, TNFR2 also contributes to T effector cell function and macrophage-TNFR2 recently was shown to promote disease development in the experimental autoimmune encephalomyelitis (EAE) model of MS. We here demonstrate that systemic administration of a TNFR2 agonist alleviates peripheral and central inflammation, and reduces demyelination and neurodegeneration, indicating that protective signals induced by TNFR2 exceed potential pathogenic TNFR2-dependent responses. Our behavioral data show that systemic treatment of female EAE mice with a TNFR2 agonist is therapeutic on motor symptoms and promotes long-term recovery from neuropathic pain. Mechanistically, our data indicate that TNFR2 agonist treatment follows a dual mode of action and promotes both suppression of CNS autoimmunity and remyelination. Strategies based on the concept of exogenous activation of TNFR2 therefore hold great promise as a new therapeutic approach to treat motor and sensory disease in MS as well as other inflammatory diseases or neuropathic pain conditions.
Note:
Gesehen am 29.10.2019
In:
Brain, behavior and immunity, Orlando, Fla. [u.a.] : Elsevier, 1987, 81(2019), Seite 247-259, 1090-2139
In:
volume:81
In:
year:2019
In:
pages:247-259
In:
extent:13
Language:
English
DOI:
10.1016/j.bbi.2019.06.021
URL:
http://www.sciencedirect.com/science/article/pii/S0889159119303782
Bookmarklink
